"I may have missed it, but the low eGFR patients did not have improved kidney fucntion (in the data I have viewed), they had lowered MACE events."

Just to clarify, we have not seen change in eGFR data for the CKD sub-population with baseline eGFR<60. All we have seen is that for the total BETonMACE population (median eGFR 99), there was a -0.4 change w/ apabetalone and a +2.1 change in placebo. Keeping in mind starting from median 99, both changes are clinically insignificant. What we need to see is those 259 patients in the CKD substudy with a median baseline eGFR of 49. Right now, ~90% of the eGFR data in the total 2425 patient population is comprised of patients w/ baseline eGFR >60 and a total population median of 99. We need to see those 10% CKD patients.

The only CKD subgroup data so far is the amazing ~50% RRR for 3-point MACE (see slide 19) 

BDAZ